197 related articles for article (PubMed ID: 24971661)
21. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
22. Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer.
Girard D; Marino FE; Cannon J
Clin Physiol Funct Imaging; 2014 May; 34(3):209-17. PubMed ID: 24119067
[TBL] [Abstract][Full Text] [Related]
23. Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation.
Galvão DA; Taaffe DR; Spry N; Joseph D; Turner D; Newton RU
Prostate Cancer Prostatic Dis; 2009; 12(2):198-203. PubMed ID: 18852703
[TBL] [Abstract][Full Text] [Related]
24. Resistance training and reduction of treatment side effects in prostate cancer patients.
Galvão DA; Nosaka K; Taaffe DR; Spry N; Kristjanson LJ; McGuigan MR; Suzuki K; Yamaya K; Newton RU
Med Sci Sports Exerc; 2006 Dec; 38(12):2045-52. PubMed ID: 17146309
[TBL] [Abstract][Full Text] [Related]
25. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study.
Hansen PA; Dechet CB; Porucznik CA; LaStayo PC
PM R; 2009 Nov; 1(11):1019-24. PubMed ID: 19942188
[TBL] [Abstract][Full Text] [Related]
26. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer.
Boxer RS; Kenny AM; Dowsett R; Taxel P
Aging Male; 2005; 8(3-4):207-12. PubMed ID: 16390748
[TBL] [Abstract][Full Text] [Related]
27. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health.
Koncarevic A; Cornwall-Brady M; Pullen A; Davies M; Sako D; Liu J; Kumar R; Tomkinson K; Baker T; Umiker B; Monnell T; Grinberg AV; Liharska K; Underwood KW; Ucran JA; Howard E; Barberio J; Spaits M; Pearsall S; Seehra J; Lachey J
Endocrinology; 2010 Sep; 151(9):4289-300. PubMed ID: 20573726
[TBL] [Abstract][Full Text] [Related]
28. Resistance Exercise Reduces Body Fat and Insulin During Androgen-Deprivation Therapy for Prostate Cancer.
Winters-Stone KM; Dieckmann N; Maddalozzo GF; Bennett JA; Ryan CW; Beer TM
Oncol Nurs Forum; 2015 Jul; 42(4):348-56. PubMed ID: 26148314
[TBL] [Abstract][Full Text] [Related]
29. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
Chen Z; Maricic M; Nguyen P; Ahmann FR; Bruhn R; Dalkin BL
Cancer; 2002 Nov; 95(10):2136-44. PubMed ID: 12412167
[TBL] [Abstract][Full Text] [Related]
30. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
31. Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen-deprivation therapy.
Newton RU; Jeffery E; Galvão DA; Peddle-McIntyre CJ; Spry N; Joseph D; Denham JW; Taaffe DR
BJU Int; 2018 Dec; 122(6):986-993. PubMed ID: 29750398
[TBL] [Abstract][Full Text] [Related]
32. Targeting muscle signaling pathways to minimize adverse effects of androgen deprivation.
de Rooy C; Grossmann M; Zajac JD; Cheung AS
Endocr Relat Cancer; 2016 Jan; 23(1):R15-26. PubMed ID: 26432470
[TBL] [Abstract][Full Text] [Related]
33. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.
Smith MR; Morton RA; Barnette KG; Sieber PR; Malkowicz SB; Rodriguez D; Hancock ML; Steiner MS
J Urol; 2013 Jan; 189(1 Suppl):S45-50. PubMed ID: 23234631
[TBL] [Abstract][Full Text] [Related]
34. A randomised controlled trial to evaluate the efficacy of a 6 month dietary and physical activity intervention for prostate cancer patients receiving androgen deprivation therapy.
Haseen F; Murray LJ; O'Neill RF; O'Sullivan JM; Cantwell MM
Trials; 2010 Aug; 11():86. PubMed ID: 20704726
[TBL] [Abstract][Full Text] [Related]
35. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
[TBL] [Abstract][Full Text] [Related]
36. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
[TBL] [Abstract][Full Text] [Related]
37. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Tannock IF; Fizazi K; Ivanov S; Karlsson CT; Fléchon A; Skoneczna I; Orlandi F; Gravis G; Matveev V; Bavbek S; Gil T; Viana L; Arén O; Karyakin O; Elliott T; Birtle A; Magherini E; Hatteville L; Petrylak D; Tombal B; Rosenthal M;
Lancet Oncol; 2013 Jul; 14(8):760-8. PubMed ID: 23742877
[TBL] [Abstract][Full Text] [Related]
38. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Karlan BY; Oza AM; Richardson GE; Provencher DM; Hansen VL; Buck M; Chambers SK; Ghatage P; Pippitt CH; Brown JV; Covens A; Nagarkar RV; Davy M; Leath CA; Nguyen H; Stepan DE; Weinreich DM; Tassoudji M; Sun YN; Vergote IB
J Clin Oncol; 2012 Feb; 30(4):362-71. PubMed ID: 22184370
[TBL] [Abstract][Full Text] [Related]
39. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
40. Long-term effects of intermittent androgen suppression therapy on lean and fat mass: a 33-month prospective study.
Spry NA; Taaffe DR; England PJ; Judge JS; Stephens DA; Peddle-McIntyre C; Baker MK; Newton RU; Galvão DA
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):67-72. PubMed ID: 22907511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
